BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients

Azacitidine is the leading compound to treat patients suffering myelodysplastic syndrome (MDS) or AML with less than 30% of blasts, but a majority of patients is primary refractory or rapidly relapses under treatment. These patients have a drastically reduced life expectancy as compared to sensitive...

Descripción completa

Detalles Bibliográficos
Autores principales: Cluzeau, Thomas, Robert, Guillaume, Mounier, Nicolas, Karsenti, Jean Michel, Dufies, Maeva, Puissant, Alexandre, Jacquel, Arnaud, Renneville, Aline, Preudhomme, Claude, Cassuto, Jill-Patrice, Raynaud, Sophie, Luciano, Frederic, Auberger, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2012
Materias:
Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3380582/
https://www.ncbi.nlm.nih.gov/pubmed/22577154

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3380582/
https://www.ncbi.nlm.nih.gov/pubmed/22577154

Ejemplares similares